Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.

NCT Number	NCT06563245
Lead Sponsor	Children's Cancer Group, China Collaborators: Shanghai Children's Medical Center, Najing Children's Hospital, West China Second University Hospital, Qilu Hospital of Shandong University, Tianjin Medical University Cancer Institute and Hospital, Tongji Hospital, Xiangya Hospital of Central South University, The First Affiliated Hospital of Zhengzhou University, The Second Hospital of Anhui Medical University, Children's Hospital of Hebei Province, Children's Hospital of Henan Province, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin +1 more
Enrollment	96 participants
Start Date	2024-09-25
Primary Completion	2029-11-15 (estimated)
Study Completion	2039-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-19